Deutsche Bank transitions Buy rating to Valeant Pharmaceuticals (VRX); Biovail and Valeant Complete Merger
Tweet Send to a Friend
Deutsche Bank transitions Buy rating to Valeant Pharmaceuticals International (NYSE: VRX), price target $30.
Deutsche analyst says, "Biovail ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Deutsche analyst says, "Biovail ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE